ABL Bio develops dual-antibody therapeutics targeting immuno-oncology diseases and degenerative brain disorders, utilizing a platform that enhances drug delivery across the blood-brain barrier. Their approach addresses the limitations of existing treatments by improving efficacy and safety profiles for patients with hard-to-treat conditions.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing treatments for immuno-oncology diseases and degenerative brain disorders often face challenges in effectively reaching the target site and may have limited efficacy or significant side effects. Delivering therapeutic antibodies across the blood-brain barrier (BBB) remains a significant hurdle in treating neurological conditions.
Solution
ABL Bio develops dual-antibody therapeutics designed to improve treatment outcomes for cancer and neurodegenerative diseases. The company's proprietary platform enhances the delivery of drugs across the blood-brain barrier, increasing the concentration of therapeutics in the central nervous system. By targeting specific pathways and utilizing a dual-antibody approach, ABL Bio aims to improve the efficacy and safety profiles of its drug candidates. Their immuno-oncology pipeline focuses on bispecific antibodies to enhance immune responses against tumors, while their neurodegenerative disease program leverages BBB-penetrating antibodies to target key proteins involved in disease progression. ABL Bio is also developing antibody-drug conjugates (ADCs) with improved therapeutic indices for hematologic malignancies.
Target Audience
ABL Bio's primary target audience includes patients with cancer and neurodegenerative diseases, as well as pharmaceutical companies seeking innovative therapeutic candidates for licensing or co-development.
Features
- Bispecific antibody platform designed to maximize efficacy and minimize toxicity in immuno-oncology
- BBB-shuttle platform (Grabody-B) for enhanced delivery of therapeutic antibodies to the brain
- Pipeline of therapeutic antibodies and ADCs targeting a range of cancers and neurodegenerative diseases
- Optimization of antibody structure to improve stability, reduce immunogenicity, and enhance target binding
- Development of ADCs with improved pharmacokinetic properties for the treatment of rare blood cancers